|
Mar 6
|
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
|
|
Feb 26
|
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
|
|
Oct 3
|
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
|
|
Oct 3
|
Chief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc
|
|
Sep 29
|
ARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors
|
|
Sep 29
|
3 Small Biotech Stocks That Could Be Stars
|
|
Aug 10
|
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
|